Expert Highlights Low Complications, Positive Cosmetic Outcomes in Breast Conservation Therapy for Multiple Ipsilateral Breast Cancer

Video

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota discusses the incidence of complications and patient-reported outcomes associated with breast conservation therapy for multiple ipsilateral breast cancer.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Judy C. Boughey, MD, about safety data and patient reported outcomes following breast conservation therapy in patients with multiple ipsilateral breast cancer in the phase 2 ACOSOG Z11102 (Alliance) trial (NCT01556243).

According to Boughey, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, results from the trial highlighted low rates of complications related to breast-conserving surgery such as the development of a hematoma. She also described some of the positive cosmetic outcomes reported among patients who have received the procedure.

Transcript:

Generally, breast conserving therapy is a well-accepted procedure [and] has relatively low morbidity. Complications in terms of general breast-conserving therapy would either be a development of a hematoma or a seroma, but we had relatively acceptable and low rates of any complications related to breast conserving surgery.

The other aspect of breast-conserving therapy, which is the radiation to the whole breast and this particular protocol required radiation boosts to each of the lumpectomy sites. We previously published that the actual cosmetic outcomes on these patients were very good. The patient-reported outcome at 2 years was good or excellent in over 70% of the patients.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Related Content